A Phase 2 Trial on the Effect of Low-Dose versus High-Dose Vitamin D Supplementation on Bone Mass in Adults with Neurofibromatosis 1 (NF1)
Abstract
This is a study to determine if a higher daily dose of vitamin D in adults with neurofibromatosis type 1 (NF1) who have a vitamin D insufficiency is safe, and decreases rate-of-loss of bone mineral density. Usually, skin exposure to ultraviolet radiation is ample for adequate levels of vitamin D. However, for those who need supplementation, the usual dose is 600 IU of vitamin D3 orally per day. Individuals with NF1 have lower 25-hydroxy vitamin D levels than the unaffected population, and they tend to have osteopenia (low bone mineral density), even at relatively young ages. This study aims to determine if higher daily doses of vitamin D3 (4,000 IU) lead to preservation of bone mineral density in both men and women between 25 and 40 years of age who have NF1 and have insufficient levels of serum 25-OH vitamin on initial screening.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2022
- Accession Number
- AD1202713
Entities
People
- David Viskochil
Organizations
- University of Utah